NASDAQ:SNSE

Sensei Biotherapeutics (SNSE) Stock Forecast, Price & News

$1.46

0.00 (0.00%)

(As of 06/1/2023 ET)

Compare

Today's Range: $1.46
▼
$1.55
50-Day Range: $1.31
▼
$1.81
52-Week Range: $1.28
▼
$2.39

Volume: 13,317 shs
Average Volume: 20,748 shs
Market Capitalization: $45.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Sensei Biotherapeutics MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.95% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.38
Upright™ Environmental Score
News Sentiment: 0.56
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.31) to ($1.56) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

1233rd out of 1,980 stocks

Pharmaceutical Preparations Industry

617th out of 978 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Sensei Biotherapeutics.

5.0

Short Interest

Percentage of Shares Shorted
0.95% of the float of Sensei Biotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
Sensei Biotherapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sensei Biotherapeutics has recently decreased by 15.46%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Sensei Biotherapeutics does not currently pay a dividend.
Dividend Growth
Sensei Biotherapeutics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Sensei Biotherapeutics has received a 77.43% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Basic medical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Sensei Biotherapeutics is -0.38.

2.0

News and Social Media Coverage

News Sentiment
Sensei Biotherapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Sensei Biotherapeutics this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for SNSE on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sensei Biotherapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
19.90% of the stock of Sensei Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 20.59% of the stock of Sensei Biotherapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sensei Biotherapeutics are expected to decrease in the coming year, from ($1.31) to ($1.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sensei Biotherapeutics is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sensei Biotherapeutics is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sensei Biotherapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Receive SNSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SNSE Stock News Headlines

June 1, 2023 | finance.yahoo.com

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 31, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

June 2, 2023 | Edge On The Street (Ad)

The Graphite Shortage Story You're Not Being Told

Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.

May 10, 2023 | markets.businessinsider.com

Citigroup Remains a Buy on Sensei Biotherapeutics (SNSE)

May 9, 2023 | finance.yahoo.com

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

April 23, 2023 | americanbankingnews.com

Sensei Biotherapeutics (NASDAQ:SNSE) Shares Down 16.6%

April 20, 2023 | finance.yahoo.com

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

April 18, 2023 | finance.yahoo.com

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

June 2, 2023 | Edge On The Street (Ad)

How to Invest in AI's Fast-Growing Market

The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.

April 13, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

March 31, 2023 | americanbankingnews.com

Sensei Biotherapeutics (NASDAQ:SNSE) Posts Quarterly Earnings Results

March 31, 2023 | americanbankingnews.com

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) to Post Q1 2023 Earnings of ($0.35) Per Share, Oppenheimer Forecasts

March 30, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium

March 28, 2023 | finance.yahoo.com

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

March 21, 2023 | finance.yahoo.com

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

March 14, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

March 7, 2023 | finance.yahoo.com

Sensei Biotherapeutics Adopts Stockholder Rights Agreement

March 6, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare Conference

February 21, 2023 | finance.yahoo.com

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

February 16, 2023 | technews.tmcnet.com

Sensei Biotherapeutics to Participate in Citi's 2023 Virtual Oncology Leadership Summit

February 16, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit

February 14, 2023 | finance.yahoo.com

Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

February 6, 2023 | msn.com

Sensei in agreement with National Cancer Institute for solid tumors candidate

February 6, 2023 | finance.yahoo.com

Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody

January 5, 2023 | markets.businessinsider.com

Sensei Biotherapeutics Enters Clinical Supply Agreement With Regeneron For Libtayo

January 5, 2023 | finance.yahoo.com

Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors

December 12, 2022 | technews.tmcnet.com

Newman Ferrara LLP Announces Corporate Governance Investigations of Sensei Biotherapeutics, Inc. (SNSE)

See More Headlines

SNSE Price History

30 days | 90 days | 365 days | Advanced Chart

SNSE Company Calendar

Last Earnings: 3/28/2023
Today: 6/02/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNSE
CUSIP: N/A
CIK: 1829802
Web: www.senseibio.com
Phone: 240-243-8000
Fax: N/A
Employees: 56
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-48,590,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -42.32%
Return on Assets: -37.60%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 13.00
Quick Ratio: 13.00

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.06 per share
Price / Book: 0.48

Miscellaneous

Outstanding Shares: 30,980,000
Free Float: 24,816,000
Market Cap: $45.08 million
Optionable: Not Optionable
Beta: -0.18

Key Executives

Mr. John K. Celebi M.B.A. (Age 50)
MBA, Pres, CEO & Director
Comp: $792.98k

Ms. Erin Colgan (Age 41)
Chief Financial Officer
Comp: $453.19k

Dr. Steven A. Fuller
Chief Biopharmaceuticals Devel. Officer

Dr. Edward Van der Horst Ph.D.
Chief Scientific Officer

Ms. Lora Pike
VP of Investor Relations & Communications

Mr. Christopher Gerry J.D.
VP & Gen. Counsel

Mr. Patrick Stephen Gallagher M.B.A.
M.P.H., Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SNSE Stock - Frequently Asked Questions

Should I buy or sell Sensei Biotherapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNSE shares.
View SNSE analyst ratings or view top-rated stocks.
How have SNSE shares performed in 2023?: Sensei Biotherapeutics' stock was trading at $1.49 at the start of the year. Since then, SNSE stock has decreased by 2.3% and is now trading at $1.4550.
View the best growth stocks for 2023 here.
Are investors shorting Sensei Biotherapeutics?: Sensei Biotherapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 154,800 shares, a drop of 15.5% from the April 30th total of 183,100 shares. Based on an average daily trading volume, of 79,100 shares, the short-interest ratio is currently 2.0 days. Currently, 1.0% of the shares of the company are sold short.
View Sensei Biotherapeutics' Short Interest.
When is Sensei Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our SNSE earnings forecast.
How were Sensei Biotherapeutics' earnings last quarter?: Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) announced its earnings results on Tuesday, March, 28th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.01.
When did Sensei Biotherapeutics IPO?: (SNSE) raised $100 million in an IPO on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO.

What is Sensei Biotherapeutics' stock symbol?: Sensei Biotherapeutics trades on the NASDAQ under the ticker symbol "SNSE."
Who are Sensei Biotherapeutics' major shareholders?: Sensei Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.40%), Bank of America Corp DE (0.29%) and Two Sigma Advisers LP (0.08%). Insiders that own company stock include Apeiron Investment Group Ltd, Cambrian Biopharma Inc, James Peyer, Robert Hamilton Pierce and Thomas G Ricks.
View institutional ownership trends.
How do I buy shares of Sensei Biotherapeutics?: Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sensei Biotherapeutics' stock price today?: One share of SNSE stock can currently be purchased for approximately $1.46.
How much money does Sensei Biotherapeutics make?: Sensei Biotherapeutics (NASDAQ:SNSE) has a market capitalization of $45.08 million. The company earns $-48,590,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.
How can I contact Sensei Biotherapeutics?: Sensei Biotherapeutics' mailing address is 1405 RESEARCH BLVD SUITE 125, ROCKVILLE MD, 20850. The official website for the company is www.senseibio.com. The company can be reached via phone at 240-243-8000 or via email at ir@senseibio.com.

This page (NASDAQ:SNSE) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial